» Articles » PMID: 10845896

High Levels of Factor IX Increase the Risk of Venous Thrombosis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2000 Jun 14
PMID 10845896
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated plasma levels of factor VIII (> 150 IU/dL) are an important risk factor for deep vein thrombosis (DVT). Factor VIII is the cofactor of factor IXa in the activation of factor X. The risk of thrombosis in individuals with an elevated factor IX level is unknown. This study investigated the role of elevated factor IX levels in the development of DVT. We compared 426 patients with a first objectively diagnosed episode of DVT with 473 population controls. This study was part of a large population-based case-control study on risk factors for venous thrombosis, the Leiden Thrombophilia Study (LETS). Using the 90th percentile measured in control subjects (P(90) = 129 U/dL) as a cutoff point for factor IX levels, we found a 2- to 3-fold increased risk for individuals who have factor IX levels above 129 U/dL compared with individuals having factor IX levels below this cutoff point. This risk was not affected by adjustment for possible confounders (age, sex, oral contraceptive use, and high levels of factor VIII, XI, and vitamin K-dependent proteins). After exclusion of individuals with known genetic disorders, we still found an odds ratio (OR) of 2.5 (95% confidence interval [CI]: 1.6-3.9). The risk was higher in women (OR: 2.6, CI: 1.6-4.3) than in men (OR: 1.9, CI: 1.0-3.6) and appeared highest in the group of premenopausal women not using oral contraceptives (OR: 12.4, CI: 3.3-47.2). These results show that an elevated level of factor IX is a common risk factor for DVT. (Blood. 2000;95:3678-3682)

Citing Articles

Blood coagulation factor IX: structural insights impacting hemophilia B therapy.

Bos M, van Diest R, Monroe D Blood. 2024; 144(21):2198-2210.

PMID: 38996207 PMC: 11600082. DOI: 10.1182/blood.2023023276.


Effect of Breastfeeding Duration on Coagulation in Women With and Without History of Gestational Diabetes Mellitus.

Fritsche L, Loffler D, Kantartzis K, Flehmig G, Roden M, Fritsche A J Clin Endocrinol Metab. 2024; 109(10):2571-2578.

PMID: 38487818 PMC: 11403320. DOI: 10.1210/clinem/dgae172.


A novel factor IXa-specific enzyme-linked immunosorbent assay detects factor IXa in human plasma.

Misenheimer T, Lasarev M, Kumfer K, Sheehan J, Schwartz B Res Pract Thromb Haemost. 2024; 8(1):102338.

PMID: 38433974 PMC: 10907220. DOI: 10.1016/j.rpth.2024.102338.


Association between venous thromboembolism-associated genetic variants, coagulation factor levels, and thrombin generation potential.

Han J, Li-Gao R, de Mutsert R, Rosendaal F, van Hylckama Vlieg A EJHaem. 2024; 5(1):47-54.

PMID: 38406509 PMC: 10887265. DOI: 10.1002/jha2.863.


A study of recurrent life-threatening thrombosis accompanied with the duplication of the factor IX gene.

Wei X, Zhang H, Chen W, Zhang J, Dai J Thromb J. 2024; 22(1):1.

PMID: 38169400 PMC: 10759697. DOI: 10.1186/s12959-023-00570-8.